EUVIMEDEUVIMED entdecken
Kohortenstudie

JAK inhibitor retention and adverse event–related discontinuation in elderly patients with rheumatoid arthritis: a real-world cohort study

In-Woon Baek, Ju Hee Choi, Seung Min Jung, Yune-Jung Park, Kyung-Su Park, Ki-Jo Kim

Clinical Rheumatology · 2026-12 · 45 (12) · 7281-7293

DOI: 10.1007/s10067-026-08499-9 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Rheumatology, online erschienen am 31.10.2026. Verfasst von In-Woon Baek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Janus Kinase Inhibitors, Antirheumatic Agents. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Rheumatoid arthritis (RA) in elderly patients poses management challenges due to comorbidities and polypharmacy. JAK inhibitors offer oral-administration advantages, but their safety in the elderly remains uncertain.

Method

We compared the retention and discontinuation reasons of JAK inhibitors in patients with RA who initiated therapy at age ≥ 65 versus < 65 years in a real-world setting. We included 317 patients with RA treated with JAK inhibitors at a single tertiary center (2000–2025), classified as ≥ 65 years (H65Y, n = 97) or < 65 years (L65Y, n = 220). The outcomes were retention and cause-specific discontinuation, with a single primary reason per patient. Drug retention was estimated by Kaplan–Meier analysis and compared using the log-rank test; factors associated with discontinuation were assessed by multivariable Cox regression.

Results

No statistically significant difference in overall retention was detected between the groups (HR [95% CI] 1.18 [0.419, 1.714], log-rank p = 0.680). However, discontinuation due to adverse effects was significantly more frequent in the H65Y group (10/20 [50.0%] vs. 6/52 [11.5%]). No cardiovascular- or malignancy-related discontinuations were observed in the H65Y group; however, given the limited cohort size and follow-up, the study was underpowered to detect these infrequent outcomes. Concomitant methotrexate (HR 2.94) or glucocorticoid (HR 3.73) use was associated with subsequent discontinuation. Herpes zoster incidence was significantly higher in the H65Y group (adjusted HR 1.94 [95% CI] 1.02–3.71; p = 0.044), with approximately half of the cases occurring within the first treatment year.

Conclusions

No statistically significant difference in JAK inhibitor retention between the elderly and younger groups was detected. Because this study assessed reasons for discontinuation rather than systematically ascertained safety events, it does not permit conclusions regarding cardiovascular or malignancy safety. Herpes zoster, particularly during the early treatment phase, warrants heightened vigilance in elderly patients initiating JAK inhibitor therapy. Key Points • No significant difference in JAK inhibitor retention between the elderly and younger groups was detected. • As only the primary reason for discontinuation was recorded, this study does not assess cardiovascular or malignancy safety; its findings pertain to drug retention and adverse event–related discontinuation. • Herpes zoster risk was significantly higher in elderly patients, mostly within the first treatment year, warranting early vigilance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidJanus Kinase InhibitorsAntirheumatic AgentsHumansFemaleMaleAgedMiddle AgedRetrospective StudiesCohort StudiesAge FactorsKaplan-Meier EstimateAged, 80 and over

Stichwörter der Autor:innen

Elderly patientsJAK inhibitorRetentionRheumatoid arthritis

Substanzen

Janus Kinase InhibitorsAntirheumatic Agents

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. md21c@catholic.ac.kr.

Zitieren

APA

Baek, I. W., Choi, J. H., Jung, S. M., Park, Y. J., Park, K. S., & Kim, K. J. (2026). JAK inhibitor retention and adverse event–related discontinuation in elderly patients with rheumatoid arthritis: a real-world cohort study. Clinical Rheumatology, 45(12), 7281-7293. https://doi.org/10.1007/s10067-026-08499-9

Vancouver

Baek IW, Choi JH, Jung SM, Park YJ, Park KS, Kim KJ. JAK inhibitor retention and adverse event–related discontinuation in elderly patients with rheumatoid arthritis: a real-world cohort study. Clinical Rheumatology. 2026;45(12):7281-7293. doi:10.1007/s10067-026-08499-9

BibTeX
@article{Baek2026,
  author = {Baek, In-Woon and Choi, Ju Hee and Jung, Seung Min and Park, Yune-Jung and Park, Kyung-Su and Kim, Ki-Jo},
  title = {JAK inhibitor retention and adverse event–related discontinuation in elderly patients with rheumatoid arthritis: a real-world cohort study},
  journal = {Clinical Rheumatology},
  year = {2026},
  volume = {45},
  number = {12},
  pages = {7281--7293},
  doi = {10.1007/s10067-026-08499-9}
}
Kostenlos starten →